Imperial College London
Portrait Picture

DrBenJones

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Clinical Senior Lecturer in Metabolic Medicine
 
 
 
//

Contact

 

ben.jones

 
 
//

Location

 

Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Padam:2022:10.1136/openhrt-2022-002184,
author = {Padam, P and Barton, L and Wilson, S and David, A and Walji, S and De, Lorenzo F and Ray, K and Jones, B and Cegla, J},
doi = {10.1136/openhrt-2022-002184},
journal = {Open Heart},
title = {Lipid-lowering with inclisiran: areal-world single-centre experience},
url = {http://dx.doi.org/10.1136/openhrt-2022-002184},
volume = {9},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Objective The reduction in circulating low-density lipoprotein cholesterol (LDL-c) is the primary aim of lipid-lowering therapies as a method of atherosclerotic cardiovascular disease risk reduction. Inclisiran is a new and potent lipid-lowering drug that is shown to be effective in reducing LDL-c in randomised controlled trials, however, real-world data of its use are not yet known. We sought to analyse the early effects of this drug in a tertiary centre lipid and cardiovascular risk clinic.Methods We performed a retrospective analysis of the first 80 patients who received a single dose of inclisiran at our lipid clinic between 1 December 2021 and 1 September 2022. Data were collected using electronic healthcare records. Baseline blood tests were taken prior to start of treatment and were repeated at 2 months follow-up. Data on adverse events were also recorded.Results At 2 months after treatment initiation, mean baseline LDL-c fell from 3.5±1.1 mmol/L by 48.6% to 1.8±1.0 mmol/L and total cholesterol from 5.7±1.3 mmol/L by 33.3% to 3.8±1.1 mmol/L (both p<0.0001). Mean high-density lipoprotein-c rose by 7.7% to 1.4±0.4 mmol/L (p=0.02) and median triglycerides fell by 31.3% to 1.1 mmol/L (IQR 0.9–2) (p=0.001). Adverse events (injection site reaction, fatigue and headache) were recorded in three patients and all had self-resolved by time of follow-up.Conclusion Inclisiran use in line with National Institute for Health and Care Excellence guidelines led to significant lowering of LDL-c at 2 months, with efficacy similar to that reported in trials with good tolerability.
AU  - Padam,P
AU  - Barton,L
AU  - Wilson,S
AU  - David,A
AU  - Walji,S
AU  - De,Lorenzo F
AU  - Ray,K
AU  - Jones,B
AU  - Cegla,J
DO  - 10.1136/openhrt-2022-002184
PY  - 2022///
SN  - 2053-3624
TI  - Lipid-lowering with inclisiran: areal-world single-centre experience
T2  - Open Heart
UR  - http://dx.doi.org/10.1136/openhrt-2022-002184
UR  - http://hdl.handle.net/10044/1/101963
VL  - 9
ER  -
Download